Compounds and compositions as modulators of GPR119 activity

A compound selected from Formula I:

• or the pharmaceutically acceptable salts thereof;
• in which:
• n is selected from 0, 1, and 2;
• R1 is selected from —S(O)2X2R4a —C(O)OX2R4aand —C(O)X2R4a, X2OR4a;
• wherein
• X2 is selected from a bond and C1-4 alkylene;
• R4a is selected from hydrogen, C1-6alkyl, halo-substituted-C1-6alkyl, hydroxy-substituted-C1-6alkyl, phenyl, and, C3-8heterocycloalkyl;
• wherein said heterocycloalkyl of R4a is optionally substituted with C1-6alkyl or —C(O)OX4R5c;
• wherein X4 is C1-4alkylene;
• R5c is C1-6alkyl;
• R2 is halo
• R20 is selected from hydrogen and methyl;
• W2 is selected from CR7 and N;
• wherein R7 is selected from hydrogen and halo;
• Y1 is selected from CH2 and C(O);
• or Y1 and W2 taken together can form a double bond where W2 is C and Y1 is CH;
• Y2, Y6 and Y7 are independently selected from N and CH, where at least one of Y2, Y6 and Y7 is CH;
• Y5 is —CH2-;
• R3 is selected from C6-10aryl and 5-6 membered heteroaryl;
• wherein said aryl or heteroaryl of R3 is optionally substituted with 1 to 4 R14 radicals;
• wherein each R14 is independently selected from C1-6alkyl, halo, C1-6alkoxy, halo-substituted-C1-6alkyl, halo-substituted-C1-6alkoxy, and C1-10 heterocycloalkyl;
• wherein the heterocycloalkyl of R14 is optionally substituted by halo.